Grifols: Difference between revisions
Content deleted Content added
No edit summary |
No edit summary |
||
| Line 20: | Line 20: | ||
==Operations== |
==Operations== |
||
In 2007 the company had 3.6 million litres per year of blood fractionation capacity and sourced plasma from 77 plasmapheresis centres, where it collected around 2 million litres of plasma per year. |
In 2007 the company had 3.6 million litres per year of blood fractionation capacity and sourced plasma from 77 [[plasmapheresis]] centres, where it collected around 2 million litres of plasma per year. |
||
==Ownership== |
==Ownership== |
||
Revision as of 06:59, 15 July 2008
 | |
| Company type | Public (BMAD: GRF) |
|---|---|
| Industry | Pharma, chemistry |
| Founded | 1940 |
| Headquarters | Barcelona, Spain |
Key people | Victor Grifols(Chairman) |
| Products | pharmaceuticals |
| Revenue | €648.8 million (2006) |
 €45.4 million (2006) | |
Number of employees | - |
| Website | www.grifols.com |
Grifols (BMAD: GRF) is a Spanish supplier of blood products. The company also supplies devices, instruments and reagents for clinical testing laboratories.
Main products
Grifols is a major world supplier of IVIG, albumin, Factor VIII and other plasma-derived products.
Operations
In 2007 the company had 3.6 million litres per year of blood fractionation capacity and sourced plasma from 77 plasmapheresis centres, where it collected around 2 million litres of plasma per year.
Ownership
Grifols was listed on the Madrid Stock Exchange in 2006. The stock became part of the IBEX-35 Index in January 2008.
References
^ http://www.grifols.es/web/presskit/documento_5575.pdf
External links
 | This Spanish corporation or company article is a stub. You can help Wikipedia by expanding it. |